Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) have been given an average recommendation of “Hold” by the fifteen research firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $30.00.

A number of brokerages have commented on ALDR. ValuEngine downgraded Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday. Cowen and Company began coverage on Alder BioPharmaceuticals in a research note on Tuesday, September 26th. They issued an “outperform” rating and a $20.00 target price on the stock. Mizuho restated a “buy” rating and issued a $32.00 target price on shares of Alder BioPharmaceuticals in a research note on Friday, September 15th. Royal Bank Of Canada began coverage on Alder BioPharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $17.00 target price on the stock. Finally, BidaskClub upgraded Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th.

Alder BioPharmaceuticals (NASDAQ ALDR) remained flat at $11.50 during trading on Friday. The stock had a trading volume of 910,167 shares. The company’s 50-day moving average price is $11.22 and its 200 day moving average price is $14.18. The firm’s market cap is $778.71 million. Alder BioPharmaceuticals has a 52-week low of $8.60 and a 52-week high of $34.30.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, beating analysts’ consensus estimates of ($1.67) by $0.19. The firm had revenue of $0.68 million during the quarter. During the same quarter in the prior year, the business earned ($0.79) EPS. Alder BioPharmaceuticals’s quarterly revenue was up 518.2% on a year-over-year basis. Equities research analysts anticipate that Alder BioPharmaceuticals will post ($5.60) EPS for the current year.

In related news, insider Mark James Litton sold 16,520 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $12.33, for a total transaction of $203,691.60. Following the completion of the transaction, the insider now owns 116,452 shares of the company’s stock, valued at approximately $1,435,853.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.60% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc lifted its position in shares of Alder BioPharmaceuticals by 2.6% during the 2nd quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 400 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Alder BioPharmaceuticals by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,488 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 698 shares during the last quarter. Swiss National Bank lifted its position in shares of Alder BioPharmaceuticals by 2.6% during the 1st quarter. Swiss National Bank now owns 66,342 shares of the biopharmaceutical company’s stock worth $1,380,000 after purchasing an additional 1,700 shares during the last quarter. Voya Investment Management LLC lifted its position in shares of Alder BioPharmaceuticals by 8.4% during the 2nd quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 1,734 shares during the last quarter. Finally, American International Group Inc. lifted its position in shares of Alder BioPharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 28,849 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 1,910 shares during the last quarter. 76.16% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Alder BioPharmaceuticals, Inc. (ALDR) Receives Average Recommendation of “Hold” from Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/22/alder-biopharmaceuticals-inc-aldr-receives-average-recommendation-of-hold-from-analysts.html.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.